7 November 2024 in ERJ Open Research
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.Methods: We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.Results: The main molecular pathogenetic mechanisms involving vasculature (i.e.endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.Conclusions: The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.
15 September 2023 in Monaldi Archives for Chest Disease
Leprosy is a neglected disease sporadically reported in high-income countries. Skin lesion and peripheral nerve involvement represent most common manifestations. Mediastinal lymphadenopathy in the absence of superficial lymph nodes involvement is very rare. Atypical or rare clinical presentations of disease may delay diagnosis and therapy and cause potential life-threatening manifestations and disabilities. We describe the case of a 49-year-old Sinhalese man who was admitted to our hospital with a one-month history of peripheral neurological symptoms and skin lesions on lower limbs. CT scan showed the presence of mediastinal lymphadenopathies without lung parenchymal and superficial lymph nodes involvement. Endobronchial ultrasound-guided transbronchial needle aspiration showed the presence of granulomas while skin biopsy revealed dermo-hypodermic granulomas with perineural lymphohistiocytic inflammatory reaction. Fite-Faraco staining demonstrated the presence of acid-fast bacilli in both lymph nodal and skin biopsy and polymerase chain reaction was positive for Mycobacterium leprae. Multibacillary leprosy was then diagnosed.
6 April 2026 in Respiratory Medicine
The role of gastroesophageal reflux disease (GERD) and proton pump inhibitors (PPI) in fibrotic interstitial lung disease (fILD) remains unclear. We evaluated the association of GERD and PPI use with cough severity and major pulmonary outcomes in patients with fibrotic ILD. This retrospective analysis of a prospective cohort study consisted of patients with fibrotic ILD enrolled in the CAnadian REgistry for Pulmonary Fibrosis. Patients were categorized by the presence of GERD and PPI use based on patient self-report and verified by review of the medical record. We evaluated the unadjusted and adjusted association of GERD and PPI use with cough severity visual analog scale (VAS), change in lung function, and mortality. 2238 patients with fILD were included, of whom 731 had idiopathic pulmonary fibrosis. GERD was present in 777 patients (35%), with 494 (64%) of these reporting PPI use. GERD was associated with worse baseline cough severity VAS [36 mm (21-59) vs 30 mm (17-55), p = 0.007), with no difference between PPI users and non-users (p = 0.89). There was no consistent association of GERD or PPI use with change in lung function or transplant-free survival, with PPI use tending to be associated with worse outcomes only upon adjustment for age, sex, body mass index, and smoking pack-years (HR 1.31, 95%CI 1.02-1.67, p = 0.03). GERD is associated with worse cough severity in fILD, but PPI use is not associated with less cough. Neither GERD nor PPI use was consistently associated with change in lung function or transplant-free survival.